2C-B Effects: Human Evidence, Risks, Pharmacology & What We Still Don't Know

Evidence verdict: 2C-B (4-bromo-2,5-dimethoxyphenethylamine) is a serotonergic psychedelic phenethylamine with real controlled human data on acute subjective, cognitive, cardiovascular, and pharmacokinetic effects, but a much thinner safety literature than better-studied psychedelics. Controlled studies show dose-dependent psychedelic and entactogen-like effects plus transient cardiovascular stimulation. Poison-center data suggest many reported intoxications are moderate and short-lived, but severe analytically confirmed cases—including serotonin syndrome, seizures, and cerebral edema—have occurred. Long-term neurological, psychiatric, cardiovascular, and repeated-use risks remain poorly characterized. [1–9]

2C-B is a Schedule I controlled substance in the United States. This page is an educational evidence review, not a dosing guide, legal recommendation, or endorsement of illegal drug use. [12]

Quick answer: what does 2C-B do?

Controlled and observational human studies describe a mixture of psychedelic, perceptual, emotionally intensifying, and stimulant-like effects. Reported effects include altered visual perception, changes in time and sensory processing, euphoria or positive mood, increased emotional responsiveness, changes in cognition, and transient increases in blood pressure and heart rate. [1–4]

The newest controlled comparison, published in 2026, found dose-dependent subjective effects and a profile that overlapped partly with both MDMA and psilocybin while remaining pharmacologically distinct from either. The same study found transient autonomic changes and a relatively short plasma elimination half-life under controlled conditions. [1]

That does not mean street 2C-B is predictable. Clinical studies use verified material, screened participants, controlled environments, measured doses, and medical monitoring. Illicit-market material may be mislabeled, mixed, or sold under names such as “tusi” or “pink cocaine,” which frequently refers to mixtures that contain no 2C-B at all. [13]

At a glance

---

What controlled human studies actually show

2026 randomized crossover study: dose-dependent psychedelic and entactogenic effects

A 2026 double-blind, placebo-controlled crossover study compared several controlled 2C-B exposures with MDMA, psilocybin, and placebo in 24 healthy experienced participants. 2C-B produced dose-dependent subjective effects, including visual, auditory, time-perception, and altered-consciousness effects. At the highest research condition, the subjective profile overlapped with both psychedelic and entactogenic dimensions. [1]

The study also measured cardiovascular effects and pharmacokinetics. Cardiovascular stimulation was present but, under those controlled conditions, was generally lower than MDMA and comparable in some measures with psilocybin. Effects were transient. [1]

This is strong evidence for acute effects under controlled research conditions. It is not evidence that recreational use is safe, that illicit products contain the stated compound, or that the same risk applies across unmonitored settings.

2023 controlled comparison with psilocybin

A 2023 within-subject double-blind placebo-controlled study in psychedelic-experienced volunteers found that 2C-B caused acute changes in subjective experience, mood, cognition, and cardiovascular measures, with a profile distinguishable from psilocybin. [2]

This matters because older descriptions often classified 2C-B loosely as “half MDMA, half LSD.” Human data support overlap, not identity. Different serotonergic drugs can produce partially similar experiences while differing in receptor pharmacology, intensity, cognitive effects, autonomic effects, and risk. [1,2]

Earlier observational human studies

A 2018 observational study in 16 experienced users found increased blood pressure and heart rate alongside euphoria, stimulation, perceptual changes, body/surrounding alterations, and mild hallucinogenic effects in some participants. [3]

A separate study of emotional effects reported euphoria and well-being, perceptual changes, altered emotional processing, and increased reactivity to some negative emotional stimuli. [4]

These studies are useful but less controlled than randomized trials. Participants self-selected and, in some studies, self-administered the drug. That makes them supportive evidence, not a replacement for controlled safety research.

---

2C-B effects: what is reasonably established

Perception and consciousness

Controlled research supports changes in visual perception, sensory processing, time perception, body experience, and broader altered-state measures. [1–3]

A 2024 controlled memory study also found that 2C-B can alter aspects of episodic-memory encoding, reinforcing that the drug affects cognition as well as perception and mood. [10]

Mood and emotional processing

Positive mood, euphoria, stimulation, and emotional intensification appear repeatedly in human studies, but effects are not uniformly pleasant. Individual response can vary, and anxiety, confusion, agitation, and distress appear in toxicology and real-world data. [1,3–5]

Cardiovascular effects

Human studies consistently show acute autonomic stimulation, including increases in blood pressure and sometimes heart rate. [1–3]

The controlled literature is too small to define risk for people with cardiovascular disease, uncontrolled hypertension, arrhythmia vulnerability, or complex medication use. A modest average change in screened healthy volunteers should not be generalized to medically vulnerable users.

---

Toxicology: most reported poisonings are not catastrophic, but severe cases exist

A prospective Dutch poison-center study examined 2C-B exposures reported from 2016–2018. Common findings included dilated pupils, agitation/aggression, hallucinations, confusion, anxiety, hypertension, and tachycardia. Most followed cases were graded as moderate poisonings, and the clinical course was generally short-lived. [5]

That study is useful because it pushes back against both extremes: 2C-B is not accurately described as universally catastrophic, but neither is it justified to call it “safe.” Poison-center cohorts are influenced by self-report, selection, co-exposures, and uncertain product identity; only a subset of cases had analytical confirmation. [5]

Severe neurologic toxicity has been documented

A published case report described analytically confirmed 2C-B exposure followed by serotonin syndrome, epileptic seizures, and severe cerebral edema in an 18-year-old man, with prolonged neurological impairment. [6]

A case report cannot tell us how often such an event occurs. It does establish that severe toxicity is biologically and clinically possible, so statements such as “2C-B cannot cause serotonin syndrome” or “there are no serious neurological risks” are not evidence-based. [6]

---

Pharmacology: serotonin signaling is central, but simple receptor labels are misleading

2C-B belongs to the substituted phenethylamine psychedelic family. In vitro receptor work shows interactions across serotonin 5-HT2 receptor subtypes, including 5-HT2A, 5-HT2B, and 5-HT2C. [8]

Older experimental systems produced seemingly conflicting labels—low efficacy or antagonist-like findings in some 5-HT2A assays versus agonist/partial-agonist activity in others. Modern psychedelic pharmacology increasingly emphasizes assay system, signaling pathway, receptor context, and functional selectivity rather than assigning one simplistic word to a compound. [8,11]

The safe summary is:

• 2C-B has serotonin-receptor activity relevant to its psychedelic effects;
• 5-HT2A signaling is strongly implicated in the psychedelic drug class;
• other 5-HT2 subtypes and signaling pathways may contribute;
• receptor activity alone does not predict the full human experience or long-term toxicity.

Metabolism and pharmacokinetics

A 2025 human pharmacokinetic/metabolism study found that monoamine oxidase A and B and cytosolic enzymes contribute substantially to 2C-B metabolism, with CYP2D6 playing a smaller pathway role. The measured major metabolites did not activate 5-HT2A in the study’s assay. [7]

This is more precise than the older internet shorthand that 2C-B is simply “broken down by MAO” or that any specific metabolic pathway automatically predicts a clinical drug interaction.

---

Interactions: evidence is thinner than confident online charts imply

There is not a high-quality clinical interaction matrix for 2C-B. That means strong claims such as “this combination is safe” or “this specific combination always causes serotonin syndrome” usually outrun direct evidence.

The safer evidence-based boundary is:

• combining psychoactive drugs adds pharmacologic uncertainty;
• serotonergic, stimulant, or sympathomimetic combinations can plausibly increase physiological or neuropsychiatric stress;
• alcohol or sedatives can impair judgment and complicate toxicity;
• MAO pathways are involved in 2C-B metabolism, making MAO-inhibiting drugs a particularly poor area for casual inference. [7,9]

This page intentionally does not provide a combination guide or instructions for optimizing effects.

---

“Tusi” / pink cocaine is usually not 2C-B

The terminology has become badly contaminated online. DEA states that the original “tusi” concept was associated with 2C-B, but modern pink powders sold as pink cocaine or tusi rarely contain 2C-B. DEA laboratory seizures have instead contained variable mixtures such as ketamine, MDMA, methamphetamine, cocaine, fentanyl, xylazine, and other drugs. [13]

That means someone searching “2C-B pink cocaine effects” may actually be asking about an unknown polydrug mixture, not 2C-B pharmacology.

A product’s color, name, logo, taste, or seller claim cannot identify its contents.

---

Drug checking: useful for uncertainty reduction, not a safety certificate

Reagent testing can sometimes help identify whether a sample behaves consistently with a claimed substance, but it cannot establish purity, concentration, dose uniformity, or absence of every contaminant. Laboratory drug checking is more informative where available, but even confirmed identity does not make exposure medically safe.

If an exposure has already occurred, emergency assessment should be based on symptoms and vital signs, not on confidence in what the material was supposed to contain. Reviews of novel psychoactive substance toxicology emphasize that mislabeling, co-exposures, and analytical uncertainty complicate real-world cases. [9]

---

When to seek urgent medical care

After a suspected 2C-B or unknown-drug exposure, urgent medical evaluation is appropriate for severe or rapidly worsening symptoms such as:

• seizure or loss of consciousness;
• severe confusion, delirium, or uncontrollable agitation;
• chest pain, fainting, or severe cardiovascular symptoms;
• very high body temperature or marked rigidity;
• repeated vomiting with inability to stay hydrated;
• severe headache with neurological changes;
• symptoms concerning for serotonin toxicity;
• any situation where the substance may have been misrepresented or mixed with an opioid or other high-risk drug.

The analytically confirmed severe neurologic case is one reason not to assume a frightening reaction will simply “wear off.” [6]

---

What we do not know about long-term use

The strongest 2C-B studies are acute or short-term. They cannot establish:

• long-term cognitive effects;
• persistent perceptual symptoms or their frequency;
• long-term psychiatric outcomes;
• dependence risk under frequent use;
• chronic cardiovascular or valvular effects;
• neurotoxicity under repeated exposure;
• safety in pregnancy;
• safety in adolescents, older adults, or people with major medical conditions;
• long-term interaction risk with psychiatric medications.

This is why mechanistic concerns should be labeled as hypotheses unless supported by human longitudinal data. The absence of a demonstrated chronic injury signal is not proof of absence; it is also not permission to invent a specific chronic disease risk from receptor pharmacology alone.

---

Legal status in the United States

2C-B is listed as a Schedule I controlled substance under U.S. federal law. [12] State and international laws can differ, and legal status can change.

Schedule I status is a legal classification; it does not itself tell us the magnitude of every medical risk or resolve every scientific question about the drug.

---

Frequently asked questions

What are the main effects of 2C-B?

Controlled studies describe psychedelic perceptual changes, altered consciousness, emotional effects, stimulation/euphoria, and transient cardiovascular stimulation. [1–4]

Is 2C-B the same as MDMA?

No. Controlled comparisons show some overlapping entactogenic/emotional effects, but 2C-B has a stronger psychedelic-perceptual profile and distinct pharmacology. [1]

Is 2C-B the same as psilocybin?

No. Both can produce psychedelic effects, but controlled head-to-head studies show differences in intensity, subjective profile, cognition, autonomic effects, and pharmacokinetics. [1,2]

Can 2C-B cause serotonin syndrome?

It has been reported in an analytically confirmed severe poisoning case that also involved seizures and cerebral edema. That proves possibility, not frequency. [6]

Is 2C-B safe because poison-center cases are often moderate?

No. Poison-center data provide useful context but cannot establish safety, and severe cases exist. Street-product identity and co-exposures also complicate risk estimates. [5,6,9]

Is pink cocaine usually 2C-B?

No. DEA reports that modern pink powders marketed as “pink cocaine” or “tusi” rarely contain 2C-B and are often mixtures of other substances. [13]

How long do 2C-B effects last?

Controlled research shows an acute effect window lasting several hours, but duration varies with the research condition and individual. This page does not provide timing instructions for recreational use. [1,3]

---

The Hippie Scientist verdict

2C-B is better studied than many “research chemicals,” but still poorly characterized compared with established medications or the most-studied psychedelics. Controlled human research confirms acute psychedelic, emotional, cognitive, and cardiovascular effects. Toxicology data show many moderate poisonings and at least rare severe neurologic toxicity. The biggest evidence gap is no longer “does it do anything?”—it is how safe repeated real-world use is, especially with uncertain product identity and polydrug exposure.

References

1. Arikci D, et al. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with MDMA and psilocybin in a double-blind, placebo-controlled study in healthy participants. Neuropsychopharmacology. 2026. PMID: 42049943. Source: pubmed.ncbi.nlm.nih.gov
2. Mallaroni P, et al. Assessment of the Acute Effects of 2C-B vs. Psilocybin on Subjective Experience, Mood, and Cognition. Clin Pharmacol Ther. 2023. PMID: 37253161. Source: pubmed.ncbi.nlm.nih.gov
3. Papaseit E, et al. Acute Pharmacological Effects of 2C-B in Humans: An Observational Study. Front Pharmacol. 2018;9:206. PMID: 29593537. Source: pubmed.ncbi.nlm.nih.gov
4. Bouso JC, et al. Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions. PMID: 26543863. Source: pubmed.ncbi.nlm.nih.gov
5. Nugteren-van Lonkhuyzen JJ, et al. The Clinical Toxicology of 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): The Severity of Poisoning After Exposure to Low to Moderate and High Doses. Ann Emerg Med. 2020. PMID: 32507489. Source: pubmed.ncbi.nlm.nih.gov
6. Tang MHY, et al. Unexpected Serotonin Syndrome, Epileptic Seizures, and Cerebral Edema Following 2C-B Ingestion. J Forensic Sci. 2020. PMID: 31643086. Source: pubmed.ncbi.nlm.nih.gov
7. Liquid chromatography-tandem mass spectrometry-based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma. 2025. PMID: 40408905. Source: pubmed.ncbi.nlm.nih.gov
8. Rickli A, et al. Receptor interaction profiles of novel NBOMe derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology. 2015. PMID: 26318099. Source: pubmed.ncbi.nlm.nih.gov
9. Nugteren-van Lonkhuyzen JJ, et al. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances: 2C-B, 4-fluoroamphetamine and benzofurans. Drug Alcohol Depend. 2015. PMID: 26530501. Source: pubmed.ncbi.nlm.nih.gov
10. Psilocybin and 2C-B at Encoding Distort Episodic Familiarity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2024. PMID: 38942147. Source: pubmed.ncbi.nlm.nih.gov
11. Moya PR, et al. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-HT2A and 5-HT2C receptors. J Pharmacol Exp Ther. 2007. PMID: 17337633. Source: pubmed.ncbi.nlm.nih.gov
12. Electronic Code of Federal Regulations. 21 CFR § 1308.11 — Schedule I. Source: ecfr.gov
13. U.S. Drug Enforcement Administration. Pink Cocaine. DEA notes that modern “pink cocaine/tusi” seizures rarely contain 2C-B and often contain variable drug mixtures. Source: dea.gov